This is a transformative event for Celcuity, its first approved product with compelling Phase 3 data. Monitor commercial launch execution in late Q3 2026 and sNDA submission for the PIK3CA-mutated cohort. The VIKTORIA-2 first-line trial results will be the next major catalyst.
Drug in focus
CELC drug pipeline →REVTORPYK
◆ Mixed Named in this press release- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially available in the US since September 30, 2026. A supplemental NDA (sNDA) for the PIK3CA mutant indication was submitted August 26, 2026; no PDUFA goal date has been publicly confirmed yet.
- Next catalyst
- None dated
What to watchWatch for the FDA's acceptance and PDUFA goal date for the sNDA covering the PIK3CA mutant indication, which would be the next major regulatory catalyst. Also monitor Q4 2026 earnings (expected early 2027) for the first meaningful product revenue figures and prescription trends. The stock's 126.5% implied upside to the mean analyst target reflects high expectations for commercial execution, so any launch stumbles could pressure the stock further.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 15 $91.51entry
- T+1 · 4mo ago −3.52%α −2.98% · $88.29
- T+5 · 4mo ago −1.50%α −0.52% · $90.14
- T+20 · 3mo ago +0.62%α −1.72% · $92.08
- T+60 · 6w ago −25.83%α −28.37% · $67.87
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Celcuity announced FDA approval of REVTORPYK (gedatolisib) for HR+/HER2- locally advanced or metastatic breast cancer without a PIK3CA mutation, based on Phase 3 VIKTORIA-1 data showing a 76% reduction in risk of progression or death. This is the company's first approved product, transforming it from a clinical-stage biotech to a commercial-stage company, with launch expected in late Q3 2026.
Key Facts
- FDA approved REVTORPYK (gedatolisib) for HR+/HER2- locally advanced or metastatic breast cancer without PIK3CA mutation
- First and only FDA-approved therapy inhibiting all class I PI3K isoforms and mTORC1/2
- Phase 3 VIKTORIA-1: REVTORPYK triplet reduced risk of progression or death by 76% (HR=0.24) vs fulvestrant
- Median PFS: 9.3 months (triplet) vs 2.0 months (fulvestrant); ORR 32% vs 1%
- Commercial launch anticipated in late Q3 2026
- sNDA for PIK3CA-mutated cohort to be submitted in Q3 2026
- Ongoing Phase 3 VIKTORIA-2 trial in first-line advanced breast cancer
Financial Impact
First FDA approval transforms Celcuity from clinical-stage to commercial-stage; market cap $5.1B; no revenue or pricing disclosed
Risk Factors
- Commercial execution risk for a first-time launch
- Safety profile includes stomatitis (72%), rash, and hyperglycemia requiring monitoring
- Competition from existing PI3K/AKT/mTOR inhibitors and CDK4/6 combinations
- Dependence on single product for near-term revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3327323 |
Track record
26 reports on CELC
7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +26.84% at T+20 after the Jun 11, 2026 report. 8 of 12 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $62.58 Now $60.57 −3.21% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $64.37 Now $60.57 −5.90% settles Nov 23
- Nov 9, 20267d ago Press Release Bullish 5/10 Entry $70.37 to $60.57 Now $60.57 −13.93% ▼ −13.93% −12.23% vs SPY
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $66.79 to $64.37 Now $60.57 −9.31% ▼ −3.62% −6.22% vs SPY
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $69.72 to $67.05 Now $60.57 −13.12% ▼ −3.83% −3.24% vs SPY
- Oct 24, 202623d ago Press Release Bullish 6/10 Entry $65.80 to $69.13 Now $60.57 −7.95% ▲ +5.06% +6.32% vs SPY
- Oct 5, 20266w ago 3 Neutral 2/10 Entry $71.25 to $63.19 Now $60.57 −14.99% ▼ −11.31% −11.17% vs SPY
- Oct 2, 20266w ago 8-K Neutral 2/10 Entry $72.10 to $67.94 Now $60.57 −15.99% ▼ −5.77% −6.93% vs SPY
- Sep 30, 20266w ago 8-K Bullish 6/10 Entry $79.52 to $65.78 Now $60.57 −23.83% ▼ −17.28% −19.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers